Professor, Neurology, UCLA School of Medicine
Neurology
Dr. Jeff M. Bronstein, MD
|
|
Give Review
Jeff Bronstein is an expert in the field of Neurology. He went to medical school at David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a one of the best medicals schools. David Geffen School of Medicine at UCLA is ranked 13 in research and 7 in primary care medicine He received 1 awards: "Super Doctor". Jeff Bronstein is a published doctor. He has 100 publications published. The most current publication "Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson disease." Jeff M. Bronstein, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Of Pesticides and Men: a California Story of Genes and Environment in Parkinson's Disease.
- Genetic variability in ABCB1, occupational pesticide exposure, and Parkinson's Disease.
- Platelet mitochondrial activity and pesticide exposure in early Parkinson's Disease.
- The Rationale Driving the Evolution of Deep Brain Stimulation to Constant-Current Devices.
- Axon degeneration and PGC1α-mediated protection in a vertebrate model of α-synuclein toxicity.
- Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson Disease.
- The association between ambient exposure to organophosphates and Parkinson's Disease risk.
- Pooled analysis of iron-related genes in Parkinson's Disease: Association with transferrin.
- Household organophosphorus pesticide use and Parkinson's Disease.
- Pesticides that inhibit the ubiquitin-proteasome system: Effect measure modification by genetic variation in SKP1 in Parkinson׳s Disease.
- Functional paraoxonase 1 variants modify the risk of Parkinson's Disease due to organophosphate exposure.
- Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson Disease.
- Traumatic brain injury, paraquat exposure, and their relationship to Parkinson Disease.
- α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson Disease.
- Deep brain stimulation for Parkinson Disease: an expert consensus and review of key issues.
- The incidence of Parkinsonism in patients with type 1 Gaucher Disease: data from the ICGG Gaucher Registry.
- Paraoxonase 1, agricultural organophosphate exposure, and Parkinson Disease.
- Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome.
- Statin use and the risk of Parkinson Disease.
- Nonsteroidal anti-inflammatory drugs may protect against Parkinson Disease.
- Inflammatory cytokine gene polymorphisms and increased risk of Parkinson Disease.
- Peripheral proteasome and caspase activity in Parkinson Disease and Alzheimer Disease.
- Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's Disease.
- Clinical characteristics in early Parkinson's Disease in a central California population-based study.
- Bilateral neurostimulation systems used for deep Brain stimulation: in vitro study of MRI-related heating at 1.5 T and implications for clinical imaging of the Brain.
- Developmental expression of OAP-1/Tspan-3, a member of the tetraspanin superfamily.
- Psychosis in nursing home patients with Parkinson's Disease.
- Analysis of probabilistic classification learning in patients with Parkinson's Disease before and after pallidotomy surgery.
- Diagnosis and treatment of Wilson's Disease.
- Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination.
- K+ channel KV3.1 associates with OSP/claudin-11 and regulates oligodendrocyte development.
- Meeting report: consensus statement-Parkinson's Disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) confe...
- The impact of thalamic stimulation on activities of daily living for Essential tremor.
- Function of tetraspan proteins in the myelin sheath.
- Isolation and characterization of a novel oligodendrocyte-specific protein.
- Postmortem analysis of pallidotomy in Parkinson''s Disease.
- Glutathione S-transferase mu, omega, pi, and theta class variants and smoking in Parkinson''s Disease.
- Parkinson''s Disease Research Education and Clinical Centers (PADRECC): background and overview.
- Improvement of cervical Dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect.
- Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson''s Disease onset.
- Replication of GWAS associations for GAK and MAPT in Parkinson''s Disease.
- Mechanisms of rotenone-induced proteasome inhibition.
- Pallidal versus subthalamic deep-brain stimulation for Parkinson''s Disease.
- Well-water consumption and Parkinson's Disease in rural California.
- Dopamine transporter genetic variants and pesticides in Parkinson's Disease.
- Pathologic findings in retinal pigment epithelial cell implantation for Parkinson Disease.
- T-cell responses to oligodendrocyte-specific protein in Multiple sclerosis.
- Involvement of OSP/claudin-11 in oligodendrocyte membrane interactions: role in biology and Disease.
- Developmental expression of OSP/claudin-11.
- Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson Disease.
- Oligodendrocyte-specific protein (OSP) is a major component of CNS myelin.
- Stereotactic pallidotomy in the treatment of Parkinson Disease: an expert opinion.
- OSP/claudin-11 forms a complex with a novel member of the tetraspanin super family and beta1 integrin and regulates proliferation and migration of oligodendrocytes.
- Cerebrospinal fluid immunoglobulin G promotes oligodendrocyte progenitor cell migration.
- Deep Brain stimulation in intraoperative MRI environment - comparison of imaging techniques and electrode fixation methods.
- Staged bilateral pallidotomy for treatment of Parkinson Disease.
- Familial associations of Alzheimer Disease and essential tremor with Parkinson Disease.
- α-Synuclein gene may interact with environmental factors in increasing risk of Parkinson's Disease.
- Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
- A humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic.
- A conditionally immortalized glial cell line that expresses mature myelin proteins and functional GABA(A) receptors.
- Medication responsiveness of motor symptoms in a population-based study of Parkinson Disease.
- The effect of entacapone on homocysteine levels in Parkinson Disease.
- Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
- Parkinson's Disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California.
- Disrupted compaction of CNS myelin in an OSP/Claudin-11 and PLP/DM20 double knockout mouse.
- Delayed internal capsule infarctions following radiofrequency pallidotomy. Report of three cases.
- Parkinson''s Disease risk from ambient exposure to pesticides.
- Long-lasting decreases of type II calmodulin kinase expression in kindled rat Brains.
- Chromosomal localization of murine and human oligodendrocyte-specific protein genes.
- Living with Parkinson's Disease.
- Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption.
- Multisite randomized trial of deep Brain stimulation.
- Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice.
- Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson Disease: a randomized controlled trial.
- TRPM-2 expression and tunel staining in neurodegenerative Diseases: studies in wobbler and rd mice.
- Kindling induced changes in calmodulin kinase II immunoreactivity.
- Valosin-containing protein mutation and Parkinson''s Disease.
- Exclusion of the beta-subunit of type II calmodulin kinase for the wobbler spinal muscular atrophy gene.
- Regulation of type-II calmodulin kinase: functional implications.
- Calmodulin kinase II in pure cultured astrocytes.
- Prenatal ontogeny of the epidermal growth factor receptor and its ligand, transforming growth factor alpha, in the rat Brain.
- Localization of retinal calmodulin kinase.
- A retinal calmodulin-dependent kinase: calcium/calmodulin-stimulated and -inhibited states.
- CNS myelin and sertoli cell tight junction strands are absent in Osp/claudin-11 null mice.
- Decreased calmodulin kinase activity after status epilepticus.
- Dark-induced changes in activity and compartmentalization of retinal calmodulin kinase in the rat.
- Medical malpractice and access to obstetrical care in Alabama.
- The U.S. medical liability system: conceptual model and proposals for reform.
- Autophosphorylation of calmodulin kinase II: functional aspects.
- Pallido-pyramidal Syndrome.
- Practice variation in the use of interventions in high-risk obstetrics.
- The politics of U.S. health care reform.
- How rural physicians compare on cost and quality measures for Medicaid ambulatory care episodes.
- Practice variation in the use of corticosteroids: a comparison of eight data sets.
- The use of Medicaid claims as a supplementary source of information on quality of asthma care.
- Payment levels, resource use, and insurance risk of medicaid versus private insured in three states.
- Pharmacists as HIV/AIDS information resources: survey of Alabama pharmacists.
- Job Exposure Matrix (JEM)-Derived Estimates of Lifetime Occupational Pesticide Exposure and the Risk of Parkinson's Disease.
Schools
University of California At Los Angeles
UCLA Medical Center
Harbor View Medical Center
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Anterior Horn Disease
- Ataxia
- Brain Aneurysm
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- Super Doctor
Education
-
UCLA Medical Center -
Harbor - UCLA Medical Center -
David Geffen School of Medicine at UCLA
Hospital
-
Ronald Reagan UCLA Medical Center
Drug Facts
| NPI NUMBER | 1114940731 | |
| NPPES Provider LastName | BRONSTEIN | |
| NPPES Provider FirstName | JEFF | |
| NPPES Provider ZIPCode | 90095 | |
| NPPES Provider State | CA | |
| Specialty Description | Neurology | |
| Total Claim Count | 2744.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1114940731 |
| Last Name Of The Provider | BRONSTEIN |
| First Name Of The Provider | JEFF |
| View All |
Similar Doctors
|
|
Dr. Barbara S. Giesser, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Antonio V. Escueta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allan D. Wu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Callene A. Momtazee, MD |
|
|
Dr. Gail P. Ishiyama, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey L. Cummings, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence W. Myers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Natalie C. Renda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brendan R. Mull, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sierra C. Ford, DO |
|
|
Dr. Ivet Hartonian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Helen R. Rausch, MD |
|
|
Dr. Laurice T. Yang, MD |
|
|
Dr. Oana M. Dumitrascu, MD |